Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella Species-Reference-Cited by-同舟云学术

Clinical Correlation of the CLSI Susceptibility Breakpoint for Piperacillin- Tazobactam against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella Species

Published:2006-06 Issue:6 Volume:50 Page:2244-2247
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gavin Patrick J.¹,Suseno Mira T.¹,Thomson Richard B.¹,Gaydos J. Michael²,Pierson Carl L.³,Halstead Diane C.⁴,Aslanzadeh Jaber⁵,Brecher Stephen⁶,Rotstein Coleman⁷,Brossette Stephen E.⁸,Peterson Lance R.¹

Affiliation:

1. Evanston Northwestern Healthcare, Evanston, Illinois

2. Cleveland Veterans Affairs Medical Center, Cleveland, Ohio

3. Hartford Hospital, Hartford, Connecticut

4. University of Michigan Health System, Ann Arbor, Michigan

5. North Florida Pathology Associates and Baptist Health, Jacksonville, Florida

6. Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts

7. McMaster University, Hamilton Health Sciences, Hamilton, Ontario

8. MedMined, Birmingham, Alabama

Abstract

ABSTRACT We assessed infections caused by extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 μg/ml. All six urinary infections responded to treatment regardless of susceptibility.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00381-05

Reference30 articles.

1. Ahmad, M., C. Urban, N. Mariano, P. A. Bradford, E. Calcagni, S. J. Projan, K. Bush, and J. J. Rahal. 1999. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin. Infect. Dis.29:352-355.

2. Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program

3. Burgess, D. S., R. G. Hall, J. S. Lewis, J. H. Jorgensen, and J. E. Patterson. 2003. Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period. Pharmacotherapy23:1232-1237.

4. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial disk susceptibility testing. Approved standard M100-S14 15th ed. Clinical and Laboratory Standards Institute Wayne Pa.

5. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the of use β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am.17:479-501.

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shared Clavulanate and Tazobactam Antigenic Determinants Activate T-Cells from Hypersensitive Patients;Chemical Research in Toxicology;2022-09-22

2. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales;Clinical Infectious Diseases;2022-08-24

3. Comparative pharmacokinetics of ceftriaxone and tazobactam (8:1) between healthy and Escherichia coli induced diarrhoeic birds;ADMET and DMPK;2022-03-12

4. THE EFFECT OF THREE METHODS ON DISSOLVING PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM FOR INFECTION;ACTA MEDICA MEDITERR;2022

5. Beta lactam;Comprehensive Pharmacology;2022